Search Results for

Showing 1 - 1 of 1 results
  1. Spotlight on members: Spark

    Spotlight on members From hospital funding to FDA approval Spark Therapeutics develops gene therapy for inherited retinal blindness After over two decades of research and development in gene therapy, Katherine A. High, MD, co-founder, president and chief scientific officer of Spark Therapeutics, is breathing a big sigh of relief this fall. On Oct. 12, the Food and Drug Administration unanimously voted to approve voretigene neparvovec, Spark Therapeutics' gene therapy treatment for inherited b

ARVO Privacy Policy Update

We have updated our Privacy Policy. This site uses cookies to improve and enhance your user experience. By continuing your visit, you consent to the use of cookies.

Dismiss